Polycystic Kidney Disease Treatments
Find Polycystic Kidney Disease Treatments
Medications for Polycystic Kidney Disease
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Polycystic Kidney Disease.
Found 4 Approved Drugs for Polycystic Kidney Disease
Tolvaptan
Brand Names
Jynarque, Samsca
Tolvaptan
Brand Names
Jynarque, Samsca
Form: Tablet, Kit
Method of administration: Oral
FDA approval date: May 19, 2009
Classification: Vasopressin V2 Receptor Antagonist
JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). JYNARQUE is a selective vasopressin V 2 -receptor antagonist indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) ( 1 )
MetFORMIN
Brand Names
Actoplus, Alogliptin, Dapagliflozin, Glipizide, Glumetza, Glyburide, Glyburide-MetFORMIN, Invokamet, Janumet, Jentadueto, Kazano, Linagliptin, Pioglitazole, Pioglitazone, Saxagliptin, Segluromet, Sitagliptin, Synjardy, Trijardy, Xigduo, Zituvimet
MetFORMIN
Brand Names
Actoplus, Alogliptin, Dapagliflozin, Glipizide, Glumetza, Glyburide, Glyburide-MetFORMIN, Invokamet, Janumet, Jentadueto, Kazano, Linagliptin, Pioglitazole, Pioglitazone, Saxagliptin, Segluromet, Sitagliptin, Synjardy, Trijardy, Xigduo, Zituvimet
Form: Tablet, Solution
Method of administration: Oral
FDA approval date: January 24, 2002
Classification: Sodium-Glucose Cotransporter 2 Inhibitor
ACTOPLUS MET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and metformin is appropriate. Important Limitations of Use Pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. ACTOPLUS MET should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see Warnings and Precautions.
Farxiga
Generic Name
Dapagliflozin
Farxiga
Generic Name
Dapagliflozin
Form: Tablet
Method of administration: Oral
FDA approval date: January 14, 2008
Classification: Sodium-Glucose Cotransporter 2 Inhibitor
FARXIGA (dapagliflozin) is indicated: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus., To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors., To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction., To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. Limitations of Use, FARXIGA is not recommended for patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients [see Warnings and Precautions.
Empagliflozin
Brand Names
Glyxambi, Jardiance
Empagliflozin
Brand Names
Glyxambi, Jardiance
Form: Tablet
Method of administration: Oral
FDA approval date: August 01, 2014
Classification: Sodium-Glucose Cotransporter 2 Inhibitor
GLYXAMBI is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies (1.
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances